Fundraising FoxBioTrack Capital — Full Portfolio
12 tracked investments · listed companies and verified rows first
Asieris Pharmaceuticals develops and commercializes drugs and diagnostic devices focused on cancer and other therapeutic areas, including treatments for advanced solid tumors and urological conditions.
BiotechHealthtechMedical Devices
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
Co-investorsLAVLilly Asia VenturesWI Harper Group3H Health InvestmentAlwin CapitalIDG Capital+2 more
Developing novel KRAS degraders.
Burlington, US
Huaixiang Hao(Founder)in
Co-investorsMRL Ventures FundJJDC
Rapafusyn develops molecular glue therapeutics using its RapaGlue platform of non-degrading macrocyclic compounds designed to modulate hard-to-drug intracellular and transmembrane protein targets.
AI & Machine LearningBiotechDeep TechBaltimore, US
Jun O. Liu(Founder)
Co-investors3E Bioventures Capital
TYK Medicines (同源康) is a Chinese biopharmaceutical company focused on discovering and developing innovative small-molecule drugs, with a platform for designing and screening targeted-therapy compounds.
BiotechHealthtech
Co-investorsAddor Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
BionovaGenor BiopharmaHaihe BiopharmaInnogenLigatechOBiOOnCusp
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.